美国芝加哥当地时间2025年5月30日至6月3日，一年一度的美国临床肿瘤学会（ASCO）年将盛大开启！作为肿瘤领域的年度盛会，其将一如既往地带来最前沿的肿瘤研究进展与诊疗理念，备受领域关注！当前，ASCO官网发布了2025 ASCO年会的摘要标题，【肿瘤资讯】特此整理骨髓瘤领域的重磅研究，带大家先睹为快！
Oral Abstract Session
口头报告专场
摘要号：7500
报告人：Aurore Perrot, MD, PhD | Toulouse University, CHU Oncopole
英文标题：MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial
中文标题：适合移植新诊断多发性骨髓瘤患者艾沙妥昔单抗卡菲佐米来那度胺地塞米松（IsaKRD）诱导后以MRD为指导的治疗策略：3期MIDAS试验主要终点
摘要号：7501
报告人：Philippe Moreau, MD, PhD | University Hospital Hôtel-Dieu
英文标题：Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negat
中文标题：适合移植新诊断多发性骨髓瘤患者中，皮下注射达雷妥尤单抗联合硼替佐米/来那度胺/地塞米松（VRd）及达雷妥尤单抗+来那度胺维持治疗对持续微小残留病阴性分析
摘要号：7502
报告人：Francesca Gay, MD, PhD | Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino
英文标题：Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)
中文标题：新诊断多发性骨髓瘤患者采用卡菲佐米-来那度胺-地塞米松联合或不联合艾沙妥昔单抗治疗后的持续微小残留病(MRD)阴性（III期IsKia试验）
摘要号：7503
报告人：Carl Ola Landgren, MD, PhD | Myeloma Program and Experimental Therapeutics Program, University of Miami
英文标题：Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial
中文标题：新诊断多发性骨髓瘤患者采用卡菲佐米、来那度胺、地塞米松（KRd）联合或不联合达雷妥尤单抗（D）的随机多中心研究：ADVANCE临床试验
摘要号：7504
报告人：Hang Quach, MD, FRACP, FRCPA | St Vincent’s Hospital Melbourne, University of Melbourne
英文标题：Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1
中文标题：非适合移植新诊断多发性骨髓瘤患者中，埃纳妥单抗联合达雷妥尤单抗和来那度胺(EDR)的初步研究结果（MagnetisMM-6 part 1）
摘要号：7505
报告人：Niels W.C.J. van de Donk, MD, PhD | Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology
英文标题：First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results
中文标题：JNJ-79635322（JNJ-5322）新型三特异性抗体在复发/难治性多发性骨髓瘤患者中的首次人体研究：1期初步结果
摘要号：7506
报告人：Xavier P. Leleu, MD, PhD | Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402
英文标题：Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study
中文标题：艾沙妥昔单抗皮下给药（OBDS系统）与静脉注射联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤随机、非劣效性3期IRAKLIA研究结果
摘要号：7507
报告人：Peter M. Voorhees, MD | Atrium Health / Levine Cancer Institute, Wake Forest University School of Medicine
英文标题：Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM)
中文标题：CARTITUDE-1试验中复发/难治性多发性骨髓瘤患者接受ciltacabtagene autoleucel (cilta-cel)治疗后的≥5年长期缓解与生存
Rapid Oral Abstract Session
快速口头报告
摘要号：7509
报告人：Lisa B. Leypoldt, MD | University Medical Center Hamburg-Eppendorf
英文标题：Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial
中文标题：高危新诊断多发性骨髓瘤适合移植患者中艾沙妥昔单抗、卡菲佐米、来那度胺及地塞米松（Isa-KRd）方案：GMMG-CONCEPT试验全队列首次报告
摘要号：7514
报告人：Eben I. Lichtman, MD | UNC Lineberger Comprehensive Cancer Center
英文标题：Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results
中文标题：ISB 2001：针对BCMAxCD38xCD3的新型三特异性抗体在复发/难治性多发性骨髓瘤患者中的首次人体1期剂量递增研究结果
本文数据源于ASCO官网.
排版编辑：Ashelin
苏公网安备32059002004080号
